This result matters beyond a convenient dosing form. Oral medications reach different patients and reduce barriers tied to needles, clinic visits, and stigma around injectable care. Changes in physical activity documented alongside weight loss suggest that biology and behavior may reinforce each other: feeling better can make moving easier, and moving more can support longer-term outcomes. Safety findings that match what clinicians already know make it easier to weigh risks and benefits for individual patients.
For readers curious about how this pill could reshape access and daily life, the full article explores details that tie the trial findings to real-world use. Learn how these results might affect treatment choices, who could benefit most, and what this means for equity in obesity care.
Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels. With a safety profile consistent with existing treatments, experts see it as a breakthrough for patients preferring oral options.